Missouri AG Gives Lilly Nov. 26 Deadline on 340B Data — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Catherine Hanaway sent Lilly an Oct. 26 cease-and-desist letter over its requirement that hospitals provide claims data to receive 340B discounts.
- Hanaway maintained that Lilly broke its promise to sell medicines through the 340B Drug Pricing Program to eligible Missouri hospitals.
- Hanaway alleged that Lilly made false and misleading statements and violated state law by imposing the claims-data policy.
- University of Missouri Health Care recently agreed to provide claims data; the health system operates seven hospitals across Missouri.
- Eli Lilly allegedly denied the health system discounts on its medicines even after that agreement, and Hanaway asked it to end the policy by Nov. 26.
Why it matters: Hanaway says the seven-hospital University of Missouri Health Care supplied claims data yet still was denied 340B discounts. Her Nov. 26 deadline puts Lilly’s participation in the federal program under state legal scrutiny, while the dispute joins a broader pushback from other states.
Ask SkimNews
